Scholarlink

<p>Pulmonary, renal and cardiovascular diseases as well as osteoporosis, must always be considered in the treatment of patients with inflammatory rheumatic diseases. Regardless of whether they are an organ manifestation of the underlying rheumatic disease, a&#xa0;medication side effect or a&#xa0;comorbidity, these diseases have a&#xa0;decisive influence on morbidity, mortality and the treatment decisions. This article is part&#xa0;1 of a&#xa0;CME article containing information on current diagnostic and therapeutic recommendations for pulmonary and cardiovascular comorbidities. The newest American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) guidelines on cardiovascular manifestations are discussed and the guideline recommendations as well as insights into current therapeutic studies on the diagnostics and treatment of frequent pulmonary comorbidities in inflammatory rheumatic diseases are presented.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management von pulmonalen und kardiovaskulären Komorbiditäten bei rheumatologischen Erkrankungen

  • 期刊论文

  • 发表日期：

    2025年7月30日

查看全文
  • P. Xanthouli,
  • A. Schatz,
  • R. Bergner,
  • K. Triantafyllias

摘要

Pulmonary, renal and cardiovascular diseases as well as osteoporosis, must always be considered in the treatment of patients with inflammatory rheumatic diseases. Regardless of whether they are an organ manifestation of the underlying rheumatic disease, a medication side effect or a comorbidity, these diseases have a decisive influence on morbidity, mortality and the treatment decisions. This article is part 1 of a CME article containing information on current diagnostic and therapeutic recommendations for pulmonary and cardiovascular comorbidities. The newest American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) guidelines on cardiovascular manifestations are discussed and the guideline recommendations as well as insights into current therapeutic studies on the diagnostics and treatment of frequent pulmonary comorbidities in inflammatory rheumatic diseases are presented.